Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 7.96 is 14% above its 3-year average of 6.95, around the middle of its 3-year range (0.00–14.93).
As of the fiscal period ended Tuesday, June 30, 2026. 19.12% below its 12-month average of 9.84.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 7.96.
QUICK RATIO (ACID-TEST)
7.96
QUICK RATIO (ACID-TEST) AVG TTM
9.84
QUICK RATIO (ACID-TEST) AVG 3Y
6.95
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-19.12%
CURRENT VS 3Y AVG
+14.49%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.96
median of 518 covered companies
CURRENT VS SECTOR MEDIAN
+168.49%
vs the sector median at left
Beta Bionics, Inc.
Market Cap
$866.05M
Quick Ratio (Acid-Test)
7.96
TTM Avg
9.84
3Y Avg
6.95
5Y Avg
N/A
Market Cap
$864.21M
Quick Ratio (Acid-Test)
14.93
TTM Avg
20.63
3Y Avg
16.30
5Y Avg
22.70
Market Cap
$851.97M
Quick Ratio (Acid-Test)
9.52
TTM Avg
4.26
3Y Avg
6.09
5Y Avg
7.80
Market Cap
$892.20M
Quick Ratio (Acid-Test)
16.16
TTM Avg
3.88
3Y Avg
3.97
5Y Avg
4.50
Market Cap
$892.87M
Quick Ratio (Acid-Test)
81.42
TTM Avg
11.94
3Y Avg
8.59
5Y Avg
10.34
Market Cap
$827.55M
Quick Ratio (Acid-Test)
3.15
TTM Avg
4.21
3Y Avg
3.84
5Y Avg
4.13
Market Cap
$821.12M
Quick Ratio (Acid-Test)
3.86
TTM Avg
4.02
3Y Avg
3.56
5Y Avg
3.80
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | $866.05M | 7.96 | 9.84 | 6.95 | N/A |
| Apnimed, Inc. (APMD)vs › | $864.96M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $864.21M | 14.93 | 20.63 | 16.30 | 22.70 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $851.97M | 9.52 | 4.26 | 6.09 | 7.80 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $892.20M | 16.16 | 3.88 | 3.97 | 4.50 |
| Arbutus Biopharma Corp (ABUS)vs › | $892.87M | 81.42 | 11.94 | 8.59 | 10.34 |
| Alumis Inc. (ALMS)vs › | $835.64M | 6.74 | 5.17 | 5.15 | 5.15 |
| Ardelyx, Inc. (ARDX)vs › | $827.55M | 3.15 | 4.21 | 3.84 | 4.13 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $821.12M | 3.86 | 4.02 | 3.56 | 3.80 |
| Bioventus Inc. (BVS)vs › | $916.63M | 1.17 | 1.03 | 0.92 | 1.05 |
Quick Ratio
7.96
Excludes inventory
Current Ratio
8.88
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 7.96 |
| 2026-03-31 | 9.67 |
| 2025-12-31 | 7.96 |
| 2025-09-30 | 9.83 |
| 2025-06-30 | 13.79 |
| 2025-03-31 | 14.93 |
| 2024-12-31 | 5.66 |
| 2024-09-30 | 3.99 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 9.65 |
| 2023-09-30 | 0.00 |
